Clinical performance validation of a novel biomarker for quantitative imaging of coronary artery disease.
Synektik SA obecnie realizuje niniejszy projekt w ramach działalności CBR.
Beneficjent: Synektik SA
Wartość dofinansowania: 3 687 250 EUR
Projekt finansowany w ramach: European Union’s Horizon 2020 Research and Innovation programme.
Synektik received funds for the project: “Clinical performance validation of a novel biomarker for quantitative imaging of coronary artery disease” under grant greement No 711083.
